<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cayman Journal - Quince Therapeutics Inc (QNCX)</title>
    <description>Latest news, press releases, and SEC filings for Quince Therapeutics Inc (QNCX)</description>
    <link>https://caymanjournal.com/stock/QNCX</link>
    <language>en-us</language>
    
    <copyright>Copyright 2026, Cayman Journal</copyright>
    <managingEditor>editorial@caymanjournal.com (Editorial Team)</managingEditor>
    <webMaster>webmaster@caymanjournal.com (Web Master)</webMaster>
    <lastBuildDate>Mon, 27 Apr 2026 20:33:41 GMT</lastBuildDate>
    <ttl>60</ttl>
    <atom:link href="https://caymanjournal.com/stock/QNCX/feed.xml" rel="self" type="application/rss+xml" />
    <image>
      <url>https://caymanjournal.com/logo.png</url>
      <title>Cayman Journal</title>
      <link>https://caymanjournal.com</link>
      <width>144</width>
      <height>144</height>
    </image>

    <item>
      <title>10-K — Quince Therapeutics, Inc.</title>
      <description># 🧾 What This Document Is
This is Quince Therapeutics&apos; 10-K, which is its **annual report** filed with the SEC. Think of it as the company&apos;s full-year report card for investors, covering everything from finances to risks. This one tells a story of a company in serious trouble after a major clinical</description>
      <link>https://caymanjournal.com/stock/QNCX/sec-filing/0001193125-26-151364</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/QNCX/sec-filing/0001193125-26-151364</guid>
      <pubDate>Fri, 10 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item>
  </channel>
</rss>